Comparing the efficacy and safety of Q-switched and picosecond lasers in the treatment of nevus of Ota: a systematic review and meta-analysis

• Published in: Lasers in medical science Vol. 36; no. 4; pp. 723 - 733
• Main Authors: Williams, Natalie M., Gurnani, Pooja, Long, Jun, Reynolds, John, Pan, Yue, Suzuki, Takahiro, Alhetheli, Ghadah I., Nouri, Keyvan
• Format: Journal Article
• Language: English
• Published: London Springer London 01.06.2021; Springer Nature B.V
• Subjects: Adverse events; Alexandrite; Dentistry; Hyperpigmentation; Lasers; Medicine; Medicine & Public Health; Meta-analysis; Nevus; Optical Devices; Optics; Original Article; Photonics; Pigmentation; Q switched lasers; Quantum Optics; Ruby lasers; Safety; Scars; Semiconductor lasers; YAG lasers; Pigmented lesions; Picosecond lasers; Q-switched lasers; Dermatology; Nevus of Ota
• DOI: 10.1007/s10103-020-03125-9
• ISSN: 0268-8921

Nevus of Ota is cosmetically burdensome and often prompts patients to seek treatment. Lasers are commonly used in removing these lesions; however, no systemic analysis has been conducted to support a gold standard laser. To conduct a meta-analysis of the efficacy and safety of Q-switched Nd:YAG lasers (QSNL), Q-switched ruby lasers (QSRL), Q-switched alexandrite lasers (QSAL), and picosecond alexandrite lasers (PSAL) in removing nevus of Ota. Inclusion criteria were nevus of Ota patients treated with QSNL, QSRL, QSAL, or PSAL and documentation of percent clearance and the rate of at least one adverse event. Articles in English, Chinese, or Japanese were included. The prespecified outcome measures were efficacy (percent clearance) and safety (rates of hyperpigmentation, hypopigmentation, scarring, and recurrence). The review included 57 studies and 13,417 patients. The pooled success rate was 64% for QSNL (95% CI 52–76%), 54% for QSRL (95% CI 39–69%), 58% for QSAL (95% CI 44–72%), and 100% for PSAL (95% CI 98–102%). The pooled adverse event rate was 5% for QSNL (95% CI 4–6%), 14% for QSRL (95% CI 9–19%), 9% for QSAL (95% CI 6–12%), and 44% (95% CI 31–57%) for PSAL. QSNL has the most evidence for effectively and safely treating nevus of Ota. PSAL potentially has a superior efficacy; however, further studies are needed to elucidate its side effect profile when treating nevus of Ota.